Theradaptive Secures FDA Approval to Advance OASIS Trial to Pivotal Study Evaluating OsteoAdapt® SP in Spinal Fusion (opens in new tab)

Theradaptive, Inc. today announced that the U.S. FDA has granted approval for the Company to initiate the pivotal Phase 3 clinical trial evaluating OsteoAdapt® SP, its next-generation regenerative therapeutic for spinal fusion procedures. The post Theradaptive Secures FDA Approval to Advance OASIS Trial to Pivotal Study Evaluating OsteoAdapt® SP in Spinal Fusion appeared first on Orthopedics This Week.